Prescribing Trends of Glaucoma Medication in Korea from 2007 to 2020: A Nationwide Population-based Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jul 11

PMID 38990957

Authors

Kyeong Ik Na

Won June Lee

Youn Joo Choi

Sung Pyo Park

Affiliations

Soon will be listed here.

Abstract

Purpose: Investigating long-term trends in glaucoma medication.

Methods: All patients diagnosed with glaucoma and prescribed glaucoma eye drops between 2007 and 2020 in Korea's Health Insurance Review and Assessment Service database participated in this study. A weight was assigned to each prescription using the reciprocal of the total number of prescriptions received by the individual in that year. The number of patients who received each type of glaucoma eye drop prescription was calculated by summing the weights for each year.

Results: During the study period, prostaglandin analog eye drop monotherapy was the most frequently given type of glaucoma eye drop prescription. Until 2008, the second most frequently given type of glaucoma eye drop prescription was beta blocker eye drop monotherapy; thereafter, it changed to carbonic anhydrase inhibitor/beta blocker fixed-combination eye drop monotherapy. The prescription proportion of single-ingredient glaucoma eye drops decreased (-1.290%/year, P < 0.001), whereas that of fixed-combination glaucoma eye drops increased (1.291%/year, P < 0.001). The number of glaucoma eye drops prescribed per patient remained constant (-0.00030/year, P = 0.167) with an average of 1.302, while the number of active ingredients prescribed per patient increased (0.01737/year, P < 0.001) from 1.659 in 2007 to 1.896 in 2020.

Conclusion: Over 14 years, there was no change in the number of glaucoma eye drops prescribed to individual patients in Korea. However, the number of active ingredients prescribed increased owing to the increased prescription of fixed-combination eye drops. The current trends in glaucoma medication are expected to help establish future treatment strategies.

References

Sugimoto M, Sugimoto M, Uji Y . Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can J Ophthalmol. 2002; 37(6):342-5. DOI: 10.1016/s0008-4182(02)80004-7. View

Wright T, Freedman S . Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009; 18(5):395-8. DOI: 10.1097/IJG.0b013e31818624e5. View

. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998; 126(4):487-97. DOI: 10.1016/s0002-9394(98)00223-2. View

Park J, Cho H, Moon J . Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011; 55(1):22-7. DOI: 10.1007/s10384-010-0904-z. View

Perera N, Pinnuck B, Jamieson M, Ling D, Williams M, Chen O . Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017. J Glaucoma. 2019; 29(3):175-183. DOI: 10.1097/IJG.0000000000001414. View

Lin J . The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007. J Glaucoma. 2015; 24(5):364-71. DOI: 10.1097/IJG.0b013e31829ea2e6. View

Hart J, Shafranov G . Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol. 2004; 137(4):756-7. DOI: 10.1016/j.ajo.2003.09.002. View

Kass M, Heuer D, Higginbotham E, Johnson C, Keltner J, Miller J . The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-13; discussion 829-30. DOI: 10.1001/archopht.120.6.701. View

Heijl A, Leske M, Bengtsson B, Hyman L, Bengtsson B, Hussein M . Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10):1268-79. DOI: 10.1001/archopht.120.10.1268. View

10.

Peplinski L, Albiani Smith K . Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004; 81(8):574-7. DOI: 10.1097/01.opx.0000141791.16683.4a. View

11.

Schwartz G . Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005; 16(2):114-21. DOI: 10.1097/01.icu.0000156139.05323.26. View

12.

Sakamoto M, Kitamura K, Kashiwagi K . Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database. J Ophthalmol. 2017; 2017:7642049. PMC: 5684567. DOI: 10.1155/2017/7642049. View

13.

Francis B, Du L, Berke S, Ehrenhaus M, Minckler D . Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study. J Clin Pharm Ther. 2004; 29(4):375-80. DOI: 10.1111/j.1365-2710.2004.00574.x. View

14.

Casson R, Chidlow G, Wood J, Crowston J, Goldberg I . Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012; 40(4):341-9. DOI: 10.1111/j.1442-9071.2012.02773.x. View

15.

Konstas A, Maskaleris G, Gratsonidis S, Sardelli C . Compliance and viewpoint of glaucoma patients in Greece. Eye (Lond). 2000; 14 Pt 5:752-6. DOI: 10.1038/eye.2000.197. View

16.

Korsch E, Grote A, Seybold M, Soditt V . Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur J Pediatr. 1999; 158(8):685. DOI: 10.1007/pl00008324. View

17.

Olthoff C, Schouten J, van de Borne B, Webers C . Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005; 112(6):953-61. DOI: 10.1016/j.ophtha.2004.12.035. View

18.

Yu L, Ding K, Luo L, Yu Z . Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017. PLoS One. 2020; 15(1):e0227595. PMC: 6957137. DOI: 10.1371/journal.pone.0227595. View

19.

Inoue K, Okayama R, Higa R, Sawada H, Wakakura M, Tomita G . Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination. J Ocul Pharmacol Ther. 2011; 27(6):581-7. DOI: 10.1089/jop.2011.0057. View

20.

Plager D, Whitson J, Netland P, Vijaya L, Sathyan P, Sood D . Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. J AAPOS. 2009; 13(4):384-90. DOI: 10.1016/j.jaapos.2009.04.017. View